By Chris Wack
Microbot Medical shares were up 38% at $1.70 after the company reported a highly successful extended joint pre-clinical animal study held for its Liberty surgical robotic system at a leading European-based research lab.
The company said that a team of six European interventional radiologists used the system and performed a total of 48 catheterizations to pre-determined vascular targets including distal branches of hepatic, gastric, splenic, mesenteric, renal, and hypogastric arteries, with a 100% success rate of reaching the intended target.
According to Microbot, based on real-time user feedback, the interventional radiologists found the system intuitive, easy to set up and use, and were impressed with the ability to control procedures remotely via the Liberty system’s remote controller.
The company plans on performing pre-clinical studies in the U.S. and other target markets, as well as its first-in-human case in markets outside the U.S. in preparation for the continued progression toward commercialization of the system.
Write to Chris Wack at chris.wack@wsj.com
Read the full article here
